Janssen

Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis
Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis
Biopharma Reporter
Janssen
JNJ
rheumatoid arthritis
nipocalimab
clinical trials
Flag link:
J&J books manufacturing space at Fujifilm Diosynth's upcoming mega-plant in North Carolina
J&J books manufacturing space at Fujifilm Diosynth's upcoming mega-plant in North Carolina
Fierce Pharma
JNJ
Janssen
Fujifilm Diosynth Biotechnologies
CDMOs
North Carolina
Flag link:
GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy
GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy
Reuters
GSK
JNJ
hepatitis B
JNJ-3989
Janssen
Flag link:
Janssen reports data from Phase III trial of lung cancer drug
Janssen reports data from Phase III trial of lung cancer drug
Clinical Trials Arena
JNJ
Janssen
Rybrevant
clinical trials
non-small cell lung cancer
Flag link:
Janssen tackles racial gap in Phase IIIb psoriasis trial with Tremfya
Janssen tackles racial gap in Phase IIIb psoriasis trial with Tremfya
Clinical Trials Arena
Janssen
psoriasis
Tremfya
clinical trials
Flag link:
Janssen’s Tremfya maintains three years of remission in Phase II Crohn’s disease trial
Janssen’s Tremfya maintains three years of remission in Phase II Crohn’s disease trial
Clinical Trials Arena
JNJ
Janssen
clinical trials
Crohn's Disease
Tremfya
Flag link:
Janssen and Atropos partner to expedite clinical development
Janssen and Atropos partner to expedite clinical development
Clinical Trials Arena
JNJ
Janssen
Atropos Health
real world data
Flag link:
After Kenvue spinoff, J&J says it's 'uniting' Janssen and medtech segments under one brand
After Kenvue spinoff, J&J says it's 'uniting' Janssen and medtech segments under one brand
Fierce Pharma
JNJ
Janssen
Medtech
rebranding
Flag link:
J&J's patient assistance program suffers data breach, IBM says
J&J's patient assistance program suffers data breach, IBM says
Fierce Pharma
JNJ
Janssen
IBM
patient assistance programs
cybersecurity
Flag link:
FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
Janssen granted additional European Commission approval for bispecific antibody
Janssen granted additional European Commission approval for bispecific antibody
Biopharma Reporter
Janssen
JNJ
bispecific antibodies
Europe
relapsed or refractory multiple myeloma
Flag link:
The 10 drugs that CMS might wrangle into negotiations
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
CMS
Medicare
drug pricing
Bristol Myers Squibb
Janssen
Merck
Pfizer
Amgen
Boehringer Ingelheim
Pharmacyclics
AstraZeneca
Astellas
GSK
Flag link:
Janssen’s newly-merged infectious disease and vaccine unit sees significant pipeline cuts
Janssen’s newly-merged infectious disease and vaccine unit sees significant pipeline cuts
Fierce Biotech
JNJ
Janssen
infectious disease
vaccines
hepatitis
HIV
Flag link:
Janssen emerges as 11th-hour financier for Nanobiotix in $2B+ deal
Janssen emerges as 11th-hour financier for Nanobiotix in $2B+ deal
Medical Marketing and Media
JNJ
Janssen
Nanobiotix
NBTXR3
soft tissue sarcoma
Hensify
Flag link:
Janssen’s trial of plaque psoriasis therapy meets endpoints
Janssen’s trial of plaque psoriasis therapy meets endpoints
Clinical Trials Arena
Janssen
JNJ
clinical trials
JNJ-2113
plaque psoriasis
Flag link:
Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment
Clinical Trials Arena
JNJ
Janssen
Tremfya
psoriasis
real world data
Flag link:
Janssen’s Tremyfa scores success in Phase III ulcerative colitis trial
Janssen’s Tremyfa scores success in Phase III ulcerative colitis trial
Clinical Trials Arena
JNJ
Janssen
clinical trials
Tremyfa
ulcerative colitis
Flag link:
J&J Makes $245M Play to Develop Next-Gen CAR-T Therapies
J&J Makes $245M Play to Develop Next-Gen CAR-T Therapies
BioSpace
JNJ
Janssen
Cellular Biomedicine
CAR-T
diffuse large B-cell lymphoma
Flag link:
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways
Benzinga
Genmab
JNJ
Janssen
Darzalex
Flag link:
J&J claims first approval for PARP combo Akeega
J&J claims first approval for PARP combo Akeega
Pharmaphorum
JNJ
Janssen
Akeega
PARP inhibitors
metastatic castration-resistant prostate cancer
Europe
Flag link:

Pages